文献速递血管炎

在肉芽肿性多血管炎和显微镜下多血管炎中PEXIVAS减量糖皮质激素方案的真实世界应用

Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis.
PubMed 文献 · Ann Rheum Dis · 2025-01-02

这项回顾性多中心研究比较PEXIVAS减量糖皮质激素方案与标准剂量方案在ANCA相关血管炎患者中的真实世界应用,共纳入234例患者;减量方案组主要复合结局发生42/126(33%),标准剂量组20/108(19%),减量方案与主要结局独立相关,但与死亡或终末期肾病无独立关联。

要点

  • 减量糖皮质激素方案组主要复合结局发生42/126(33%),标准剂量组20/108(19%)。
  • 减量方案与主要复合结局独立相关,但与死亡或终末期肾病无独立关联。
  • 接受利妥昔单抗治疗的减量方案患者更易发生死亡或终末期肾病及主要复合结局。

核心结论

  • 在主要接受利妥昔单抗治疗的ANCA相关血管炎患者中,减量糖皮质激素方案与包含死亡、终末期肾病、缓解前疾病进展或复发的主要复合结局风险增加相关。

研究设计与样本

  • 回顾性多中心研究,比较PEXIVAS减量糖皮质激素方案与标准剂量方案在ANCA相关血管炎患者中的应用,共纳入234例患者,采用逆概率治疗加权校正组间基线不平衡。

主要发现

  • 主要复合结局在减量方案组发生42/126(33%),在标准剂量组发生20/108(19%)。
  • 在未加权多变量分析和加权分析中,减量方案与主要复合结局独立相关,但与死亡或终末期肾病无独立关联。
  • 在减量方案治疗的患者中,血清肌酐>300 µmol/L者更可能达到主要复合结局。
  • 接受利妥昔单抗治疗的减量方案患者更可能发生死亡或终末期肾病,并更可能达到主要复合结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PEXIVAS (Plasma exchange and glucocorticoids in severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis) trial showed that a reduced-dose glucocorticoid regimen (redGC) was non-inferior to a standard-dose regimen (standGC) with respect to death or end-stage kidney disease (ESKD) in patients with ANCA-associated vasculitis (AAV). However, the primary endpoint did not include disease progression or relapse, cyclophosphamide was the main induction therapy and rituximab (RTX)-treated patients tended to have a higher risk of death or ESKD with redGC. We aimed to evaluate the real-world use of redGC. METHODS: We conducted a retrospective, multicentre study comparing PEXIVAS redGC with standGC in patients with AAV. The primary composite outcome was the occurrence of death, ESKD, AAV progression before remission or relapse within the 12 months following induction. Inverse probability of treatment weighting was used to correct for baseline imbalance between groups. Factors associated with the occurrence of the primary outcome were estimated. RESULTS: A total of 234 patients were included. The primary composite outcome occurred in 42/126 (33%) patients with redGC versus 20/108 (19%) with standGC. In unweighted multivariable analysis and in weighted analysis, redGC was independently associated with the primary outcome but not with death or ESKD. Among redGC-treated patients, those with serum creatinine>300 µmol/L were more likely to achieve the primary outcome. RTX-treated patients who received redGC were more likely to experience death or ESKD and to achieve the primary outcome. CONCLUSION: In this study of patients with AAV primarily treated with RTX, redGC was associated with an increased risk of the primary outcome consisting of death, ESKD, AAV progression before remission or relapse.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Nagle S, Nguyen Y, Guerry MJ, et al. Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis. Ann Rheum Dis. 2025. PMID: 39919904. doi:10.1136/ard-2024-226339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。